Jan 26, 2025, 06:13
Shaalan Beg: Is 2025 going to be the year Pan-RAS inhibitors make it into the clinic?
Shaalan Beg, Senior Advisor for Clinical Research at the National Cancer Institute, shared a post on X:
“Is 2025 going to be the year Pan-RAS inhibitors make it into the clinic?
Pan-RAS inhibitor shows early/deep molecular response (and 36% response rate) for G12X mutated pancreatic cancer.
(Significant AEs: rash, diarrhea, nausea, vomiting).”
Pashtoon Kasi, Medical Director of GI Medical Oncology at City of Hope, shared this post on X, adding:
“GI25 finally it has a name.
DARAXonRASib
RMC – 6236 | MULTI (pan-RAS)
Also:
– Elironrasib (RMC-6291 | G12C)
– Zoldonrasib (RMC-9805 | G12D)
We are participating in the registration studies. A lot of enthusiasm about it.”
Read Full article at ASCO Daily News.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 26, 2025, 06:06
Jan 26, 2025, 05:56
Jan 26, 2025, 05:54
Jan 26, 2025, 05:45
Jan 26, 2025, 05:43
Jan 26, 2025, 05:12
Jan 25, 2025, 17:27